Alehagen Urban, Aaseth Jan Olav, Schomburg Lutz, Opstad Trine B, Larsson Anders, Alexander Jan
Division of Cardiovascular Medicine, Department of Medical and Health Sciences, Linköping University, SE-581 85 Linköping, Sweden.
Research Department, Innlandet Hospital Trust, N-2381 Brumunddal, Norway.
Antioxidants (Basel). 2025 Jun 5;14(6):685. doi: 10.3390/antiox14060685.
Low selenium intake and age-related decline of coenzyme Q (CoQ) have been associated with an increased risk of cardiovascular disease (CVD) and oxidative stress. In a randomised placebo-controlled trial (RTC) in elderly people with low selenium levels, the supplementation with selenium and CoQ reduced CVD and mortality. However, whether the supplementation elicited sex-specific benefits remained to be explored. Elderly Swedish persons ( = 443; balanced sex ratio) receiving selenium yeast (200 µg/day) and CoQ (200 mg/day) combined or a placebo for four years were followed for additional six years. The response to supplementation, cardiovascular (CV) mortality, and risk factors were determined at four and ten years. Kaplan-Meier analyses, ANCOVA, repeated measurements of variance, and Cox proportional hazard regression analyses were performed. The measured 10-year CV mortality rate was lower in females, and supplementation reduced this risk to a greater extent compared to in males. The improved survival rate apparently kicked in later in females than in males. At baseline, males had a higher smoking rate, increased inflammation and oxidative stress, and a higher prevalence of more advanced ischaemic heart disease (IHD) and signs of heart failure. When stratified by sex, in individuals with IHD, the intervention improved CV survival in both sexes, whereas supplementation had a more pronounced effect in females without IHD at inclusion. Supplementation diminished inflammation and oxidative stress, impaired the increase of NT-proBNP, and improved renal function in both sexes. : The supplementation improved CV survival, especially in women. The higher prevalence of structural CVD and smoking in males may have contributed to the observed greater supplementation benefits in females. The preventive impact of selenium and CoQ supplementation in elderly males and females may be particularly strong and meaningful in the early stages of CVD development.
低硒摄入量以及与年龄相关的辅酶Q(CoQ)水平下降与心血管疾病(CVD)风险增加和氧化应激有关。在一项针对低硒水平老年人的随机安慰剂对照试验(RTC)中,补充硒和CoQ可降低CVD和死亡率。然而,这种补充是否产生性别特异性益处仍有待探索。对443名瑞典老年人(性别比例均衡)进行了为期四年的跟踪研究,他们分别接受硒酵母(200微克/天)和CoQ(200毫克/天)联合补充或安慰剂,之后又继续跟踪了六年。在四年和十年时确定补充反应、心血管(CV)死亡率和风险因素。进行了Kaplan-Meier分析、协方差分析、重复测量方差分析和Cox比例风险回归分析。测量的10年CV死亡率在女性中较低,与男性相比,补充剂在更大程度上降低了这种风险。女性的生存率改善显然比男性出现得更晚。在基线时,男性吸烟率更高,炎症和氧化应激增加,更晚期缺血性心脏病(IHD)和心力衰竭迹象的患病率更高。按性别分层时,在患有IHD的个体中,干预改善了两性的CV生存率,而在纳入时没有IHD的女性中,补充剂的效果更明显。补充剂减少了炎症和氧化应激,抑制了NT-proBNP的升高,并改善了两性肾功能。补充剂改善了CV生存率,尤其是在女性中。男性中结构性CVD和吸烟的患病率较高,这可能是观察到女性补充剂益处更大的原因。在CVD发展的早期阶段,补充硒和CoQ对老年男性和女性的预防作用可能特别强大且有意义。